Alterity Therapeutics (ATHE) EBIT Margin (2019)
Alterity Therapeutics (ATHE) posted EBIT Margin of 304.03% for Q4 2019.
Powered by 
Analysis
Alterity Therapeutics (ATHE) EBIT Margin (2019) Analysis & Trends
Alterity Therapeutics has reported EBIT Margin for 1 years, with the latest figure at 304.03% in Q4 2019.
- On a quarterly basis, EBIT Margin changed N/A year-over-year to 304.03% in Q4 2019; TTM through Dec 2019 was 790.98%, a N/A change from a year earlier, with the FY2018 full-year figure at 2847.27%, down 1015511.0% from the prior year.
- EBIT Margin was 304.03% for Q4 2019 at Alterity Therapeutics.
- The five-year high for EBIT Margin was 304.03% in Q4 2019, with the low at 304.03% in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Alterity Therapeutics | 72.80 Mn | 72.80 Mn | - | - |